Trial Profile
An Exploratory Phase II, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Pertuzumab and Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 15 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 20 Jul 2016 Study design changed from single group assignment to parallel group assignment and treatment arms changed from 1 to 2.
- 01 Apr 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.